Respiratory Insufficiency
Recent clinical, regulatory, research and industry developments relating to this disease.
ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure.
The pathophysiology of 'happy' hypoxemia in COVID-19.
Acute kidney injury in patients hospitalized with COVID-19.
Diagnosis of severe respiratory infections in immunocompromised patients.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 clinical trials expected to report results, the earliest in Q4 2026.
Clinical MilestonesViewHide
- 2026-07-16Multicenter HomeVENT: Home Values and Experiences Navigation TrackResults expected Q4 2029
- 2026-05-07Platform of Randomized Adaptive Clinical Trials in Critical IllnessResults expected Q1 2027
- 2026-01-06Partial Neuromuscular Blockade in Acute Hypoxemic Respiratory FailureResults expected Q4 2026
- 2026-05-01Doxapram Versus Placebo in Preterm Newborns: An International Double Blinded Multicenter Randomized Controlled TrialPrimary completion
- 2025-10-31The Evaluation of the Effectiveness and Safety of Nalbuphine Hydrochloride Injection for Analgesia in ICU Patients: A Multicenter, Randomized, Single-blinded, Parallel, Two-step TrialPrimary completion
- 2026-07-16ClinicalMulticenter HomeVENT: Home Values and Experiences Navigation TrackResults expected Q4 2029
- 2026-05-07ClinicalPlatform of Randomized Adaptive Clinical Trials in Critical IllnessResults expected Q1 2027
- 2026-05-01ClinicalDoxapram Versus Placebo in Preterm Newborns: An International Double Blinded Multicenter Randomized Controlled TrialPrimary completion
- 2026-01-06ClinicalPartial Neuromuscular Blockade in Acute Hypoxemic Respiratory FailureResults expected Q4 2026
- 2025-10-31ClinicalThe Evaluation of the Effectiveness and Safety of Nalbuphine Hydrochloride Injection for Analgesia in ICU Patients: A Multicenter, Randomized, Single-blinded, Parallel, Two-step TrialPrimary completion
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — 1.5-mg/0.3-ml and 2.5-mg/0.5-ml solution for injection Prevention of venous thromboemboli… (2002)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Respiratory Insufficiency2
- Betacoronavirus1
- Drug Overdose1
- Heart Arrest1
- Noninvasive Ventilation1
- Opiate Overdose1
- Pandemics1
- Respiratory Distress Syndrome1
Leading journals5
- Anesthesiology1
- Intensive care medicine1
- Kidney international1
- Respiratory research1
- The European respiratory journal1
Leading researchers8
- Azoulay E1
- Barnett RL1
- Bauer P1
- Bos L1
- Boyd J1
- Chatwin M1
- Dahan A1
- Depuydt P1
Affiliations (unnormalised)6
- Academic and Clinical Department of Sleep and Breathing and NIHR Respiratory Biomedical Research Unit1
- Baskent University1
- Careggi University Hospital1
- Center for Drug Evaluation and Research1
- Centre Hospitalier Universitaire de Poitiers1
- Clinical Epidemiology and Medical Statistics Unit1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Respiratory insufficiency is failure to adequately supply oxygen to body cells and remove excess carbon dioxide. It is a broad clinical state that can present as acute respiratory failure or hypoxemic respiratory failure in a range of settings.
The grounding supports infectious causes, especially pulmonary infection in immunocompromised patients, including bacterial pneumonia and viral respiratory infections. It also supports chemically induced causes, particularly opioid overdose causing respiratory depression.
The core mechanism is inadequate gas exchange, leading to hypoxemia and/or carbon dioxide retention. In COVID-19, one described pattern is profound hypoxemia with relatively preserved respiratory comfort, attributed in part to altered respiratory drive and oxygenation physiology. Opioid-induced respiratory insufficiency occurs through suppression of respiratory drive, producing respiratory depression.
Immunocompromised status increases risk for acute hypoxemic respiratory failure due to severe respiratory infections. Exposure to opioids, especially long-acting opioids or opioids with high µ-opioid receptor affinity or slow receptor dissociation, increases risk of respiratory depression and insufficiency.
Management includes oxygen support and noninvasive respiratory support modalities such as high-flow nasal cannula, conventional oxygen therapy, and noninvasive ventilation in acute respiratory failure. When respiratory insufficiency is opioid-induced, naloxone is the specific reversal agent used to counter respiratory depression. In infectious causes, early antibiotic therapy is part of management, although it may reduce microbiologic diagnostic yield.
AI-generated summary grounded in MeSH and 4 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed)
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.